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The hypothesis that cytomegalovirus (CMV) modulates cancer is evolving. Originally
discovered in glioblastoma in 2002, the number of cancers, where intratumoral CMV
antigen is detected, has increased in recent years suggesting that CMV actively affects
the pathobiology of certain tumors. These findings are controversial as several groups
have also reported inability to replicate these results. Regardless, several clinical trials
for glioblastoma are underway or have been completed that target intratumoral CMV
with anti-viral drugs or immunotherapy. Therefore, a better understanding of the possible
pathobiology of CMV in cancer needs to be ascertained. We have developed genetic,
syngeneic, and orthotopic malignant glioma mouse models to study the role of CMV
in cancer development and progression. These models recapitulate for the most part
intratumoral CMV expression as seen in human tumors. Additionally, we discovered that
CMV infection in Trp53 /+ mice promotes pleomorphic rhabdomyosarcomas. These
mouse models are not only a vehicle for studying pathobiology of the viral-tumor
interaction but also a platform for developing and testing cancer therapeutics.
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Introduction
Mounting evidence suggest a role for persistent human cytomegalovirus (HCMV) infection in
multiple types of cancer (1). The hypothesis was originally suggested in 2002 by a paper reporting
detection of HCMV-specific gene expression by immunohistochemistry (IHC) for multiple viral
proteins (HCMV-IE1 andHCMV-pp65) and in situ hybridization (ISH) for HCMVDNA in 100% of
glioblastomas and astrocytomas tested (n= 22) (2). Viral antigens were not present in normal brain
regions from the same patients or in other brain abnormalities from other patients. Using similar
sensitive techniques, other groups were able to detect HCMV in tumors (3, 4). Additionally, HCMV
infection directly correlated with the grade of glioma. Higher-grade tumors exhibited increased
HCMV immune-positive cells in the tumor. There was also increased HCMV immune-positivity
associated with higher tumor grade (4). Recent studies have provided additional evidence that
HCMV exists inmalignant glioma as well as providedmore insight into how this virusmodulates the
cancer. BesidesHCMV-IE1 and -pp65, two studies additionally foundHCMV-US28 in glioblastomas
(5, 6). HCMV-US28 is an oncomodulatory protein that is capable of activating signal transducer
and activator of transcription 3 (STAT3) (5). Other groups have focused on detecting the HCMV
genome in glioblastoma. One study detected 20 different HCMV genes in most glioblastoma cases
tested (7). The most comprehensive study sequenced HCMV in glioblastomas after detecting the
virus in 94% of tumors (8). They were able to successfully sequence part of the HCMV genome.
Interestingly, the tumor-associated sequences showed significant variability with published HCMV
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genomes. Another study correlated HCMV infection with
glioblastoma survival (9). They discovered that low-grade HCMV
infection (<25% HCMV positive cells) was associated with
long-term survival in glioblastoma patients (>18months). These
data suggest that high-viral load within the tumor significantly
decreases survival. However, it should be noted that this topic
remains highly controversial. In fact, several recent papers con-
tinue to refute the finding that HCMV is present in tumors.
One group used next generation sequencing to detect possible
viral DNA sequences in 21 malignant gliomas (10), but failed to
detect HCMV DNA. Another group similarly could not detect
HCMV DNA in 34 glioblastoma cases utilizing deep-coverage
whole-genome sequencing (11). These negative findings continue
to render the role of CMV in cancer highly controversial.
Besides malignant gliomas, HCMV protein has also been
detected in additional cancers: prostate, mucoepidermoid car-
cinoma, lung carcinoma, colorectal cancer, and breast cancer
(12–16), and we have demonstrated the presence of CMV in
rhabdomyosarcomas (RMS) (17). Further, HCMV was detected
in 92% of medulloblastomas in one study (18). In this particu-
lar report, to validate their finding in vivo, the authors treated
humanmedulloblastoma flank tumors with ganciclovir, celecoxib,
or a combination of both. Drug therapy shrunk the tumors
suggesting that HCMV presence in tumors may be a target for
drug therapy (19). The authors of one clinical trial concluded
that Valcyte is effective in extending the survival of patients
with CMV+ glioblastomas (20), although this conclusion has
been disputed by others, based on limitations of the trial design
and conduct (21). One recent report from a phase 1 trial in
Australia reported encouraging data related to safety and pos-
sible effectiveness for a CMV-targeted adoptive T cell therapy
(22). In fact, anti-CMV immunotherapy is now being tested
in multiple human trials for patients with recurrent glioblas-
toma. Therefore, in spite of the controversy, clinical trials tar-
geting CMV in tumors are proceeding, thus rendering our need
to understand the role of this tumor pathobiology even more
pressing.
In summary, although a strong association between CMV
and multiple cancer types has been suggested by the aforemen-
tioned studies, they fall short of proving a causal relationship
or unequivocally explaining the effect of HCMV infection on
cancer pathobiology. High rates of HCMV seropositivity render
epidemiological linkage ofHCMVwith uncommondiseases, such
as malignant glioma, highly difficult to demonstrate. In addition,
there is no evidence that CMV is related to or modulates cancer
in an in vivo setting. Another possibility may be that HCMV,
while not causative on its own, could still be a modulating factor
in cancer pathobiology (23). Our group has developed mouse
models to try and study the role of CMV infection in cancer
progression. To show that CMV can function as a cancer “modu-
lator,” we employed genetically engineered mouse models. Based
on the particular context of tumor suppressor mutations in the
mice, we have discovered a link between CMV and malignant
gliomas as well as RMS. In this review, we plan to provide details
of the animal methodologies employed as well as summarize
our most salient findings and discuss the need for additional
studies.
Viral Infection Methodology
To test the hypothesis that CMV affects cancer development we
combined in vivo cancer mouse models with MCMV infection
protocols. Cytomegaloviruses (CMVs) are strictly species-specific
(24, 25) and several different CMV types have been identified for
manymammals (i.e., human,mouse, guinea pig, etc.).MCMVand
HCMV are similar in size and virion structure. However, their
genomic sequences are not identical. Despite the difference in
genome sequence, MCMV is functionally homologous to HCMV.
The viruses share the same properties with respect to genome
structure (not sequence), pattern of gene expression, cell tropism,
and infectious dynamics (26–29). Therefore,MCMV is a generally
accepted model for HCMV infection, latency, reactivation, and
pathogenesis. A combination of mouse genetic and orthotopic
models were developed in order to rigorously test the complex
role of CMV in the tumors. To study the role of CMV in malig-
nant gliomas, initially we utilized the Mut3 mouse model that
spontaneously develops high-grade astrocytomas (WHOgrade III
anaplastic astrocytoma and grade IV glioblastoma) with almost
complete penetrance by adulthood (30). These mice developed
normally until they became symptomatic for glioma (i.e., seizures,
weight loss, lethargy, paralysis) as adults.
Direct intracerebral inoculation is an efficient model of neu-
rological infection, but these mice eventually succumb to viral
encephalitis (31). Unfortunately, this prohibits study of chronic
diseases such as cancer. Koontz and colleagues developed an
infection protocol using i.p. injection to study MCMV infection
in the brain (32). This model delivers MCMV via i.p. injection,
leading to systemic infection, including brain infection. In this
model, MCMV was detected in the brain at an early age, which
proved to be an ideal method to studying the role of CMV in
gliomas as it closely mimics human infection patterns.
Mut3 (GFAP-cre; Nf1loxP/+; Trp53 /+) male mice were bred
with wild type (wt) B6CBAF1/J females to generate mice of
desired genotypes (30). They were bred in a CMV-free animal
vivarium. Introducing an infectious pathogen into a vivarium is
a risky endeavor. Without careful monitoring and strict infection
protocols, unintended spread of infection can occur. We col-
laborated extensively with veterinarians and animal facility staff
to develop protocols to allow us to pursue experiments with-
out unintentionally spreading infection. Pregnant females were
transferred to an isolated vivarium that was specifically designed
to hold only infected mice, thus reducing the risk of infectious
spread to the general non-infected mouse colony. To prevent viral
spread, MCMV and mock-infected mice were housed on sepa-
rate mouse cage racks, mock-infected mice were handled before
infected mice, and cages were changed on different days. Mice
were intraperitoneally (i.p.) injected on postnatal day 2 (P2) mice
with 103 plaque forming units (p.f.u.s.) of MCMV-m157 in 100 µl
of phosphate-buffered saline (PBS) or PBS only (mock). The lack
of the m157 gene increases virulence in B6 mice (33). Another
cohort ofmice received 103 p.f.u.s. of a different neurotropic virus,
HSV1 F strain (34), via i.p. injection in 100 µl of PBS as a viral
control.
Mice infected withMCMVwere behaviorally indistinguishable
from mock-infected mice. Mice were sacrificed at desired time
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points and were perfused via an intracardiac route with PBS. Mice
for IHC were additionally perfused with 4% paraformaldehyde.
To verify infection, we sacrificed P2 mock- or MCMV-infected
mice at 8weeks of age. Mice were perfused with PBS and tissue
of interest was dissected out and total DNA was purified.
Experimental Results of Cytomegalovirus
Infection in Malignant Glioma Mouse
Models
Using the aforementioned model, MCMV-GB gene was consis-
tently detected by polymerase chain reaction (PCR) in multiple
tissues, including the brain, from MCMV- but not from mock-
infected (Figure 1A). This similar pattern has been demonstrated
by other groups and is a reliable marker of systemic infection
(35). At 3weeks of age, diffuse MCMV protein was evident in
the brain fromMCMV-, but not mock-infected mice (Figure 1B).
Additionally, regions of immunoreactivity demonstrated micro-
grial nodules as seen onH&E staining (Figure 1C, bottom), which
is consistent with data from Koontz and colleagues (32). This
suggests that MCMV infects Mut3 mice similarly to wt mice.
Additionally, MCMV reaches the brain and causes an immune
reaction as evidenced by the microglial nodules. By 7weeks of
age, MCMV-reactive cells decreased and were mostly restricted to
specific brain regions, including the hippocampus and subventric-
ular zone (Figure 1C). Reduction of MCMV antigen expression
is presumably due to immune clearance of virus and resulting
latency. Interestingly, the hippocampus and subventricular zone
are rich in neural stem cells, a cell type demonstrated to give rise to
malignant gliomas (36). We performed dual antigen IHC on cell
markers for all neural cell types to determine what cell type was
infected. MCMV did not co-stain with neural markers, but did
co-localize with CD45+ cells (Figure 1D). This data suggest that
CMV is found in lymphocytes in the brain as opposed to native
neural cells. Data from intracerebral infection models demon-
strate that MCMV infects a variety of neural cell types depending
on viral phase (29). The i.p. infection model suggests that MCMV
traffics to the brain via CD45+ immune cells. Whether this is
true in humans is yet to be determined. To differentiate whether
live virus was in brain, and that we were not just detecting viral
antigens, whole brain extracts from 2-week-old MCMV-infected
mice were plated over a monolayer of fibroblasts. Both Mut3 and
wt mice formed infectious plaques when plated on fibroblasts
in vitro (Figure 1E), indicating the presence of active MCMV
replication. There was no statistical difference in viral activity
between Mut3 and wt mice suggesting that MCMV infects both
genotypes of mice equally. Another cohort of mice was infected
with a luciferase-tagged MCMV (MCMV-luc) to study the sys-
temic spread of infection. After infection, the mice were serially
imaged to test for bioluminescence. Systemic infection peaked at
day 17 and was undetectable by day 56 (Figure 1F). This infection
pattern is consistent with patterns seen in humans: active infection
after inoculation followed by latency after the virus is cleared by
the immune system (37).
After infectionwas confirmed,Mut3miceweremonitored until
they developed signs of brain tumor burden (seizures, lethargy,
failure to thrive, etc.). MCMV-infected Mut3 mice died signifi-
cantly earlier than mock-infected Mut3 mice both as a group and
in the subset of mice in which glioma formation was confirmed
histologically (Figure 2A). Survival of mock-infected mice was
similar to published reports (30). The mean survival of Mut3
mice was decreased by 7.4 weeks in the MCMV group compared
to mock-infected mice, corresponding to an approximately 22%
shortened life span. MCMV-infected wt mice did not develop
brain tumors nor exhibit a shortened life span relative to mock-
infected wt mice. Infection of Mut3 mice with HSV1, a different
neurotropic virus, did not significantly change life span caused by
malignant gliomas when compared to controls (Figure 2B). This
suggested that the shortened life span in the context ofMut3muta-
tions was specific to perinatalMCMV infection rather than a non-
specific effect from perinatal infection with any neurotropic virus.
This is the first published evidence that CMV can impact malig-
nant gliomas using an in vivomodel. Symptomaticmice developed
gliomas (Figure 2B), some characterized as grade IV glioblas-
tomas with histological evidence of necrosis (Figure 2B, right
panel). Malignant gliomas from MCMV-infected mice demon-
strated intratumoral MCMV protein expression (Figure 2C) and
were positive for MCMV gene expression, unlike control tumors
from mock-infected Mut3 mice (Figure 2D). The expression of
intratumoral CMV is consistent with data from human stud-
ies (2, 4). This suggests that this model replicates the human
condition for the most part. In MCMV-infected mice, MCMV
expression occurs at high frequency intratumorally. Published
data demonstrate a higher number of CMV+ cells in human
tumors than seen in our murine data. One possible explana-
tion may be that intratumoral immune responses in mice sup-
press CMV expression more than seen in humans. Additionally,
humans typically live longer withmalignant gliomas thanmice do,
months as opposed to days to weeks. Perhaps, this additional time
may increase intratumoral CMV expression as seen in humans.
The final possibility is that the animal model does not com-
pletely replicate the human condition and that MCMV remains
strictly lymphocyte tropic while HCMV can infect human glioma
cells.
To further validate these findings, we then used a syngeneic,
orthotopic malignant glioma model. Intracranial injection of
malignant glioma cells cultured from Mut4 mice (GFAP-cre;
Nf1loxP/+; Trp53 /+; pTenloxP/+) (39) into the striatum of wt mice
recapitulates glioblastoma phenotypes of necrosis and microvas-
cular proliferation (40). This approach allows for the same tumor
burden to be injected into the same brain region, resulting in con-
sistent tumor formation in a pre-defined brain region. This model
thus offers some advantages compared to the model in genetically
engineered Mut3 mice. It reduces the need for genetic breeding
and allows for less variable tumor formation, both temporally and
spatially. However, it is an artificial system requiring a major pro-
cedure to inject the brain tumor cells. Wt mice were infected with
mock or MCMV at P2 were intracranially injected with MCMV-
free mouse glioblastoma cells at 8 weeks of age. MCMV-infected
wt recipients died significantly earlier than mock-infected mice.
Mean survival was decreased by 1.8 weeks, corresponding to
an approximately 19% shortened survival similar to data from
the Mut3 spontaneous glioma model. The similar reduction in
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FIGURE 1 | Perinatal MCMV infection resulted in productive virus replication and CMV immunoreactivity in CD45-positive cells in the brain.
(Continued)
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FIGURE 1 | Continued
(A) PCR analysis for MCMV glycoprotein B (GB) gene in genomic DNA obtained
from PBS-perfused mock- versus MCMV-infected, 8-week-old mice. Bl, blood;
SG, salivary gland; Cb, cerebellum; Hp, hippocampus; Cx, cortex. “+” and “ ”:
gDNA from MCMV-infected and -negative cells, respectively. (B) IHC data for
CMV in the brains of mock- versus MCMV-infected mice. Cx, cortex; CC,
corpus callosum; Hp, hippocampus. Scale bar= 100mm. (C) Top, IHC images
show ectopic cellularity (blue, arrows) close to CMV-positive cells (red) in the
cortex of 3-week-old wt mice infected with MCMV at P2, which were absent in
mock-infected mice. Bottom, hematoxylin and eosin (H&E)-stained brain
sections adjacent to the sections in top images contained an inflammatory
focus (arrow) in the MCMV mice, which was absent in mock-infected mice.
(D) Confocal images of IHC for CMV and CD45 display immunoreactivity in the
brains from 2-week-old wt mice. Cells double positive for both CMV and CD45
are pointed by arrows. Scale bar= 10mm. (E) Brain extract of 2-week-old mice
infected with MCMV formed virus-induced plaques in 3T3 cells. There was no
significant difference between wt and Mut3 (P=0.16). Error bars indicate SEM.
Inset, a representative image of plaque formation (arrows) in 3T3 cells. Scale
bar=100mm. No plaque was formed by brain extract of mock-infected mice.
(F) Bioluminescent live imaging on P17 and adult (P56) mice infected with
MCMV-luciferase. Scale bar= 1 cm. Reprinted by permission from the American
Association for Cancer Research: Price et al. (38).
FIGURE 2 | Perinatal MCMV infection shortens the survival of Mut3 mice.
(A) Kaplan–Meier curves display overall (left) and histologically glioma-confirmed
(right) survivals of Mut3 mice. Labels indicate infection groups, mouse numbers,
mean survival time, and P values against mock and HSV1 (first and second P
values, respectively). (B) Left, a representative hematoxylin and eosin
(H&E)-stained brain section from an MCMV-infected Mut3 mouse that harbors a
grade IV astrocytoma (glioblastoma) spreading extensively throughout the
forebrain. Scale bar= 500mm. Right, a higher magnification image from the
same tumor displaying extensive necrosis (arrows). Scale bar= 50mm. (C) IHC
images for CMV in gliomas from mock- versus MCMV-infected Mut3 mice.
Scale bar= 50mm. (D) RT-PCR analysis for MCMV glycoprotein B (GB) in
gliomas from mock- (i) versus MCMV-infected (ii) Mut3 mice. “+” and “ ”:
MCMV-infected and -negative cells, respectively. Reprinted by permission from
the American Association for Cancer Research: Price et al. (38).
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FIGURE 3 |MCMV analysis of mouse tumors. (A) PCR for
MCMV DNA in tumors from MCMV (n= 4) and mock-infected (n= 1)
mice. (B) RT-PCR for MCMV-IE1 in tumors from MCMV (n= 4) and
mock-infected (n= 1) mice. (C) RT-PCR product fidelity was validated by
sequencing the amplified MCMV-IE1. (D) MCMV-IE1 immunohistochemistry
in MCMV- and Mock-infected tumor. Scale bars= 50 µm. Reprinted by
permission from the American Association for Cancer Research:
Price et al. (17).
survival suggests that host infection, as opposed to intrinsic tumor
infection, leads to a more lethal tumor. This is congruent with
earlier data showing thatMCMV is active in CD45+ lymphocytes.
This infected cell type potentially modulates malignant glioma
into a more lethal phenotype via paracrine signaling.
Additionally, we created an orthotopic model using athymic
mice to study the effect of HCMV on human malignant glioma
cells. Patient-derived human GBM neurospheres were infected
with HCMV and then dissociated three days later. HCMV- or
mock-infected dissociated cells were injected in the flanks of
athymic mice and then monitored for survival. HCMV-infected
tumors grew larger. These tumors were then removed and ana-
lyzed. This technique demonstrates one method of studying the
HCMV effect on human tumors using an in vivo system. Another
group developed a similar model to study medulloblastoma (18).
This group showed the presence of HCMV in the tumor and
that these tumors could be treated with an anti-CMV agent.
Directly comparing the effects ofHCMVon human tumors allows
a better insight of what is actually occurring in humans as well
as allows the development of therapeutics to treat CMV-driven
tumors.
MCMV-Infected Trp53 /+ Mice Develop
Pleomorphic RMS
In addition to malignant gliomas, we are interested in studying
the role of CMV in other tumors. Many human tumor types
are deficient in the p53 tumor suppressor. Trp53 /+ mice were
derived fromMut3mice. Published data show thatTrp53 /+mice
develop variable tumors at a late age. Tumors from these mice
range from lymphomas to fibrosarcomas, and only rarely result in
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RMS (<10% of the time) (41). We infected these mice neonatally
with MCMV, similarly to our malignant glioma studies, or at
4 weeks of age (106 p.f.u.s) to simulate early adult MCMV infec-
tion. Since Trp53 /+ mice start developing tumors at a late
age (>9months), we terminated experiments at 9months of
age to detect MCMV-specific effects on tumor development.
We hypothesized that MCMV would lead to an earlier tumor
onset. Neonatal MCMV infection was associated with a sta-
tistically significant increase in tumor occurrence compared to
mock-infected mice. In fact, only 1 mock-infected out of 27
mice developed a tumor during our study. In contrast, 42.8%
(12/28) of neonatally MCMV-infected Trp53 /+ mice developed
tumors at significantly earlier time points when compared to
mock-infected mice. Interestingly, 84.6% (10/12) of these tumors
were pleomorphic RMS. This data suggest that, not only does
MCMV accelerate tumor formation in mice with heterozygous
Trp53mutation but preferentially leads to formation of pleomor-
phic RMS as opposed to other types of cancer. Mice infected as
adults did not show increased tumor incidence indicating that
adult infection does not promote tumor formation. Analysis of
these tumors demonstrated that MCMV genetic material was
present in tumors as was observed in human tumors. MCMV-
infected mice revealed the presence of viral DNA (Figure 3A)
in all tumors tested, but not in the mock-infected Trp53 /+
mouse. Additionally, early gene MCMV-IE1 transcripts were
present in most tumors, whereas a gene transcribed later in
the replication cycle, MCMV-GB, was not detected (Figure 3B
and not shown). We do not know why this late gene was not
transcribed, but this suggests that full viral replication is not
occurring. Instead, the virus is only transcribing certain early
transcripts. Sequencing of the transcription product from RT-
PCR reactions of MCMV-IE1 RNA revealed that the transcripts
sequenced from the tumor matches the stock virus injected into
the mice (Figure 3C). Furthermore, MCMV-infected tumors
expressed IE1 protein (Figure 3D). Strong intratumoral IHC
staining corroborates the human data. Taken together, these data
show transcriptionally active MCMV within RMS tumors, which
could modulate the tumor. These data suggest a role of CMV in
RMS development. Our data show for the first time that CMV
infection combined with Trp53 heterozygosity promotes pleo-
morphic RMS. Furthermore, the idea that CMV can promote
tumorigenesis in an organism with genetic aberrations, such as
loss of a tumor suppressor, may help to explain the difficulty
of epidemiologically linking CMV infection with relatively rare
cancers.
Conclusion
We have successfully developedmultiple mouse models to test the
role of CMV in malignant gliomas. The combination of sponta-
neous, orthotopic, and human gliomamodels can be used to study
the effect of CMV infection on cancer development. Additionally,
we infected Trp53 /+ with MCMV and discovered that these
mice develop pleomorphic RMS. Our data demonstrate that we
have created relevant, reproducible mouse models to represent
the human condition. The insight gained from these models
suggests that HCMV has an active role in tumor progression in
humans and that more investigation is necessary. Data from our
RMS studies emphasized the importance of neonatal infection
as opposed to adult infection. Additionally, MCMV expression
occurs in CD45 cells in the brain. Oncomodulatory effects occur
via paracrine signaling. After tumor formation, there is an appre-
ciable increase in MCMV expression in the tumor, but not in
other normal parts of the mouse. This is similar to IHC of human
tumors.
The mouse models can be helpful to further study the possible
role of CMV infection in cancer. Moving forward the models can
be expanded to investigate other aspects of the role that CMV
plays in cancer. As we have demonstrated, it can be adapted
to study other cancers besides malignant glioma. Other mouse
models of cancer may amenable to CMV infection and should
be implemented as the increasing number of tumor types that
contain CMV are discovered. Additionally, the role of specific
CMV proteins may be dissected by creating chimeric mouse
models that express CMV proteins in certain tissues. One model
expressing HCMV-US28 has already been developed to study
colon cancer (42). New mouse models need to be developed with
other oncomodulatory proteins. Also, humanized models that are
permissive to HCMV and capable of harboring human tumors
will powerfully mimic the human condition. Current models have
already demonstrated that anti-CMV therapies can curtail growth
of CMV-infected tumors. As better models are created in the
future, a stronger understanding of the role of HCMV in human
cancer will be garnered. Ultimately, thesemodels will hopefully be
utilized to develop cancer therapies that exploit CMV for cancer
therapeutics.
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